Champions Oncology, Inc. (CSBR) Stock Forecast
CSBR analyst forecast
as of October 18, 2026- Analyst consensus
- —
- Price target
- $12.00 average of analyst targets
- Upside to target
- +155.3% from the latest close
- Next earnings
- —
- 52-week range
- $4.70 – $7.80
CSBR price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
CSBR earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Next fiscal year (FY2027) | $0.10 | $0.10 | $0.10 | $0.12 | −16.7% | 1 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
CSBR revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Next fiscal year (FY2027) | $65.3M | $65.3M | $65.3M | +11.5% | 1 |
CSBR EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
CSBR revenue: reported and forecast
CSBR EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Next fiscal year (FY2027) | $0.15 | $0.15 | $0.15 | $0.15 | $0.10 | −33.3% | 0 up · 1 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
CSBR earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; CSBR beat in 8 of 12.
What analysts expect from CSBR
The average price target is $12.00, 155.3% above the latest close of $4.70. For FY2027 the average estimate is $0.10 per share on revenue of $65.3 million. Champions Oncology beat the EPS estimate in 8 of the last 12 quarters.
Related: CSBR income statement, CSBR key metrics, CSBR chart. See the CSBR stock overview for the latest quote and news.
CSBR forecast FAQ
What is Champions Oncology's price target?
The average analyst price target for Champions Oncology is $12.00, 155.3% above the latest close of $4.70.
Does Champions Oncology usually beat earnings estimates?
Champions Oncology reported EPS at or above the analyst estimate in 8 of the last 12 quarters.